Also written by Reutersuk:
GSK Boosts Board-Level Science as New CEO Prepares to Take Over
x hide permanently

Shire Faces Criticism on CEO Pay Policy as Crunch Week Looms

(Reuters) - Shire ( SHP.L ), the $47 billion (£33.1 billion) rare disease drugmaker being stalked by Japan’s Takeda Pharmaceutical ( 4502.T ), faces fresh criticism over its executive pay policy from a leading investor advisory group as a crunch week approaches...

Mentions: Investment CEO ISS